SIRIUS
Feb 08 2022
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene with Advanced Vision Loss (SIRIUS).
Read MoreExamining Whether AOSLO-Based Foveal Cone Metrics in Achromatopsia and Albinism Are Representative of Foveal Cone Structure.
May 03 2021
PubMed ID: 34111268 Author(s): Litts KM, Woertz EN, Wynne N, Brooks BP, Chacon A, Connor TB Jr, Costakos D, Dumitrescu A, Drack AV, Fishman GA, Hauswirth WW, Kay CN, Lam BL, Michaelides M, Pennesi ME,…
Read MoreReversal of Vision Loss in a 49-Year-Old Man With Progressive Optic Atrophy Due to Profound Biotinidase Deficiency.
Mar 01 2021
PubMed ID: 32235217 Author(s): Kellom ER, Wolf B, Rice GM, Stepien KE. Reversal of vision loss in a 49-year-old man with progressive optic atrophy due to profound biotinidase deficiency. J Neuroophthalmol. 2021 Mar 1;41(1):e27-e30. doi:…
Read MoreXOLARIS
Dec 01 2020
To gain a better understanding of disease progression over time in male subjects with X-linked retinitis pigmentosa (XLRP).
Read MoreAGTC A3
Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene Sponsor: Applied Genetic Technologies Corp…
Read MoreAGTC B3
Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene Sponsor: Applied Genetic Technologies Corp visit…
Read MoreNIGHT
Sep 30 2020
Natural History of the Progression of Choroideremia Study (NIGHT) Sponsor: NightstaRx Ltd, a Biogen Company CLINICALTRIALS.GOV
Read More